Cellebrite DI (NASDAQ:CLBT) Azioni

Cellebrite DI

Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.

Cellebrite DI Ltd

Earnings

Earnings Misses

News

BRSP

BrightSpire Capital Q1 Adj. EPS $0.16, Inline, Sales $15.85M Miss $17.60M Estimate

Legal

AREN

The Arena Group Settles Litigation With Authentic Brands Group; Terms Not Disclosed

Wall Street betting markets are on fire just hours before the first-quarter GDP release, with odds of a negative U.S. growth print soaring after months of trade war escalation and a <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">record-breaking goods deficit.</a>
According to Kalshi, a CFTC-regulated prediction market, the probability of a contraction in U.S. GDP for the first quarter surged to 65% on Tuesday, just one day before the data drop. The implied reading now point to negative 0.4%, the lowest since late February 2025. 
Odds for a positive GDP reading tumbled by 30 percentage points to 39%, implying a $100 bet would return $245 if U.S. economy averts a quarterly contraction.
The economist consensus, as tracked by Trading Economics, still projects a 0.4% annualized expansion, down sharply from the 2.8% pace recorded in the fourth quarter of 2024.
The U.S. economy has not recorded a negative quarterly growth since the first quarter of 2022.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXGDP-25APR30?color_scheme=light&#038;widget_size=large&#038;utm_campaign=benzinga_widget" width="552px" height="400px" style="border:0"></iframe>
<h3 class="wp-block-heading">Trade Deficit Smashes Records, Weighing On GDP</h3>
A major factor dragging down the GDP outlook has been the surge in America&#8217;s trade deficit, as U.S. manufacturers rushed to stockpile imports in anticipation of higher costs stemming from Donald Trump&#8216;s new tariffs.
The U.S. goods trade deficit widened to a historic $161.9 billion in March 2025, obliterating Wall Street's $145 billion estimate and marking a sharp deterioration from February's already massive $147.8 billion gap. 
January and February also recorded the second—and third-highest monthly deficits ever recorded, underscoring the persistent strain on America's trade flows.
Ballooning trade deficits directly drag GDP calculations, as net exports subtract from overall output. The bigger the deficit, the larger the negative contribution to economic growth.
<h3 class="wp-block-heading">Liberation Day Tariffs Stoke Fears of 2020-Style Shock, Analyst Says</h3>
In a note shared last week, Oskar Vårdal, macro analyst at Steno Research, said the current economic dynamics resemble those seen during the early days of the COVID-19 lockdowns in March 2020, when global supply chains collapsed and uncertainty spiraled.
"What we told hedge funds is that we are staring directly into a 2020-like shock," Vårdal said, highlighting how an external disruption—this time tariffs, not a virus—is hitting supply chains, crushing cyclical indicators and fueling dangerous feedback loops.
The Dallas Federal Reserve's latest manufacturing survey plunged to 45.3 in April, dragging the regional average for factory activity well below the 50-line that separates expansion from contraction. The broader ISM Manufacturing Index, due later this week, is still expected to come in at a subdued 48.
Larsen is speculating that a &#8220;big bond trade&#8221;—hinting at a long position in U.S. Treasuries—may be just ahead of us.
"The 48 consensus is amusingly complacent, in my honest opinion," said Steno Research strategist Andreas Steno Larsen in a post on X, suggesting that Wall Street may be underestimating the severity of the slowdown. 
Larsen said the current supply-demand dislocation mirrors the &#8220;lockdown/reopening logic&#8221; of 2020, particularly if Trump's administration gradually dials back tariffs later on.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Econ #s

Economics

Analyst Ratings

Q1 GDP Recession Bets Spike As Trump Tariffs Fuel 2020-Style Economic Shock

WIIM

Global Industrial shares are trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

MSA Safety (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSA#NYSE">MSA</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.58 by 6.33 percent. This is a 4.35 percent increase over earnings of $1.61 per share from the same period last year. The company reported quarterly sales of $421.34 million which beat the analyst consensus estimate of $402.63 million by 4.65 percent. This is a 1.94 percent increase over sales of $413.30 million the same period last year.

Earnings Beats

MSA Safety Q1 Adj. EPS $1.68 Beats $1.58 Estimate, Sales $421.34M Beat $402.63M Estimate

Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.87 by 9.2 percent. This is a 13.1 percent increase over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $1.33 billion which beat the analyst consensus estimate of $1.28 billion by 4.01 percent. This is a 6.90 percent increase over sales of $1.25 billion the same period last year.

VLTO

Veralto Q1 Adj. EPS $0.95 Beats $0.87 Estimate, Sales $1.33B Beat $1.28B Estimate

Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ("Holders") the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share ("Class B Common Stock"), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol&#xAE;&nbsp;Cyclo&#x2122; in the event of a positive interim result from the 48-week interim analysis of the TransportNPC&#x2122; Phase 3 clinical trial in Niemann-Pick Disease Type&nbsp;C1 ("NPC1").
Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025.

Biotech

Offerings

General

Rafael Holdings Announces Proposed Terms Of $25M Rights Offering To Support Its Commitment To Development And Potential Launch Of Trappsol Cyclo.

Stride shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) lowers FY2025 Adj EPS guidance from $9.12-$9.45 to $8.95-$9.28 vs $9.02 analyst estimate..

Guidance

Unum Gr Lowers FY2025 Adj EPS Guidance from $9.12-$9.45 to $8.95-$9.28 vs $9.02 Est

Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.20 by 70 percent. This is unchanged from the same period last year. The company reported quarterly sales of $93.97 million which missed the analyst consensus estimate of $96.63 million by 2.76 percent. This is a 12.04 percent increase over sales of $83.87 million the same period last year.

VICR

Vicor Q1 EPS $0.06 Misses $0.20 Estimate, Sales $93.97M Miss $96.63M Estimate

BBIO

BridgeBio Pharma shares are trading higher after the company reported better-than-expected Q1 financial results.

Springview Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) ("Springview Holdings", or the "Company"), a company which designs and constructs residential and commercial buildings in Singapore with an operating history dating back to 2002, today announced that on April 25, 2025, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's ordinary shares was below $1.00 per share for a period of 30 consecutive business days from March 13, 2025 to April 24, 2025. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker "SPHL".
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until October 22, 2025 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

SPHL

Springview Holdings Receives Nasdaq Non-Compliance Notice; Granted 180 Days to Regain $1.00 Bid Price

Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) reported second-quarter financial results after market close on Tuesday. Here&#8217;s a rundown of the report and a look at why shares are <a href="https://www.benzinga.com/pressreleases/25/04/b45082715/starbucks-reports-q2-fiscal-year-2025-results">cooling off after hours</a>.
Q2 Earnings: Starbucks reported second-quarter revenue of $8.76 billion, missing <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $8.86 billion, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The coffee giant reported second-quarter adjusted earnings of 41 cents per share, missing analyst estimates of 50 cents per share.
Consolidated net revenue was up 2% on a year-over-year basis. Global comparable store sales declined 1%, driven by a 2% decline in comparable transactions, partially offset by a 1% increase in average ticket. Comparable store sales fell 1% in North America and 2% internationally. The company said comparable store sales in China were flat in the quarter.
Starbucks opened 213 net new stores in&nbsp;the second quarter and ended the period with 40,789 total locations. The company ended the quarter with $2.67 billion in cash and cash equivalents. 
&#8220;My optimism has turned into confidence that our &#8216;Back to Starbucks&#8217; plan is the right strategy to turn the business around and to unlock opportunities ahead,&#8221; said&nbsp;Brian Niccol, chairman and CEO of Starbucks.
Don&#8217;t Miss: <a href="https://www.benzinga.com/25/04/45078739/stocks-surge-and-bond-yields-fall-for-6th-day-oil-prices-drop-to-60-whats-driving-markets-tuesday">Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What&#8217;s Driving Markets Tuesday?</a>
Starbucks suspended its guidance for fiscal year 2025 at the end of last year due to the company&#8217;s &#8220;CEO transition coupled with the current state of the business.&#8221; Niccol took over as CEO in September.
&#8220;Improving transaction comp in a tough consumer environment at our scale is a testament to the power of our brand and partners getting &#8216;Back to Starbucks.&#8217; We are on track and if anything, I see more opportunity than I imagined,&#8221; Niccol said. 
Starbucks&#8217; board declared a cash dividend of 61 cents per share, payable on May 30 to shareholders of record as of May 16.
The top- and bottom-line miss appears to be dragging shares lower after hours. 
Starbucks executives will further discuss highlights from the second quarter on a conference call with investors and analysts at 5 p.m. ET.
SBUX Price Action:&nbsp;<a href="https://www.benzinga.com/quote/SBUX" target="_blank" rel="noreferrer noopener">Starbucks shares</a>&nbsp;were down 1.24% in the after-hours session, trading at $83.80 at the time of publication Tuesday, per&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/04/45041645/coke-vs-coffee-can-coca-cola-stay-fizzy-starbucks-rebound-after-earnings">Coke Vs. Coffee: Can Coca-Cola Stay Fizzy? Starbucks&#8217; Rebound After Earnings?</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/jaanall">Cloudy Design</a>/Shutterstock.

After-Hours Center

Movers

SBUX

Starbucks Misses Q2 Earnings Estimates, CEO Says Optimism Has Turned Into Confidence: 'I See More Opportunity Than I Imagined'

Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) affirms FY2025 Adj EPS guidance from $6.00-$6.20 to $6.00-$6.20 vs $5.93 analyst estimate..

Sonoco Prods Affirms FY2025 Adj EPS Guidance of $6.00-$6.20 vs $5.93 Est

Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.09 by 122.22 percent. This is a 100 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $629.40 million which beat the analyst consensus estimate of $588.15 million by 7.01 percent. This is a 3.88 percent decrease over sales of $654.80 million the same period last year.

QUAD

Quad/Graphics Q1 Adj. EPS $0.20 Beats $0.09 Estimate, Sales $629.40M Beat $588.15M Estimate

E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) sees FY2026 sales of $600.000 million-$618.000 million vs $622.51 million analyst estimate.

ETWO

Correction: //E2open Parent Holdings Sees FY2026 Sales $600.000M-$618.000M vs $622.51M Est

JBG SMITH Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBGS#NYSE">JBGS</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is a 68.97 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $120.69 million which missed the analyst consensus estimate of $133.17 million by 9.37 percent. This is a 16.87 percent decrease over sales of $145.18 million the same period last year.

JBGS

JBG SMITH Props Q1 FFO $0.09 Misses $0.12 Estimate, Sales $120.69M Miss $133.17M Estimate

Unum Group shares are trading lower after the company reported worse-than-expected Q1 financial results,

Community Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHCT#NYSE">CHCT</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.47 by 17.02 percent. This is a 6.78 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $30.08 million which beat the analyst consensus estimate of $29.64 million by 1.47 percent. This is a 2.54 percent increase over sales of $29.33 million the same period last year.

CHCT

Community Healthcare Q1 FFO $0.55 Beats $0.47 Estimate, Sales $30.08M Beat $29.64M Estimate

Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) reported quarterly earnings of $2.98 per share which beat the analyst consensus estimate of $2.76 by 7.97 percent. This is a 56.02 percent increase over earnings of $1.91 per share from the same period last year. The company reported quarterly sales of $745.54 million which beat the analyst consensus estimate of $734.14 million by 1.55 percent. This is a 22.24 percent increase over sales of $609.89 million the same period last year.

Comments

Cellebrite DI

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO